Ensysce Biosciences, Inc. (ENSC) Stock Price & Analysis
Ensysce Biosciences, Inc. (ENSC) — MoonshotScore 19/100 (Weak band), calculated Oct 4, 2026. Price $0.395 (-1.20%), as of the Oct 2, 2026 trading session; market cap $6.07M.
Educational signal · not a buy or sell recommendation · How to read this
Ensysce Biosciences, Inc. · ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel pain relief and overdose protection technologies. Their primary focus is on creating abuse-resistant and overdose-resistant opioid prodrugs.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Ensysce Biosciences (ENSC)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $1M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 5 of 8
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 24 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak |
The score was 19 in the stored Oct 3, 2026 snapshot and remains 19 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Business Quality +1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.395 | |
| Change on the day | -1.20% | |
| 52-week range | $0.23 – $2.75 | |
| Market capitalisation | $6.07M | |
| Price / earnings (trailing) | -0.22 | |
| Shares traded on the day | 174.0K |
Price & events
Council Score · weighted blend of 2 available disciplines
Council score for Ensysce Biosciences (ENSC): Bearish Lean
31/100 · DSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ENSC film — every key number, told as a short cinematic story
~2 min · open the film
What is Ensysce Biosciences (ENSC), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ensysce Biosciences, Inc. (ENSC) is the company analyzed here. It employs 9 people and is led by D. Lynn Kirkpatrick. In Q2 FY2026 it reported revenue of $1M and net income of -$3M. The market values it at $6.07M.
What do the latest results show for Ensysce Biosciences (ENSC)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1M. Against analyst estimates the company has EPS beat 5 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1M | -$3M | -$0.20 (diluted) |
| Q1 FY2026 | $0 | -$4M | -$0.52 (diluted) |
| Q4 FY2025 | $0 | -$3M | -$0.11 (diluted) |
| Q3 FY2025 | $0 | -$4M | -$1.29 (diluted) |
What are the financial strengths and risks for Ensysce Biosciences (ENSC)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth. The distress and quality screens read Piotroski F 3. Trailing ratios: current ratio 0.70.
How does Ensysce Biosciences compare with its peers?
Short answer
Ensysce Biosciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $7.19 Oct 2, 2026 | $564M | 94 5-pillar Oct 4, 2026 | |
| $47.15 Oct 2, 2026 | $872M | 93 5-pillar Oct 4, 2026 | |
| $9.99 Oct 2, 2026 | $591M | 91 5-pillar Oct 4, 2026 | |
| $4.59 Oct 2, 2026 | $669M | 88 5-pillar Oct 4, 2026 | |
| $17.08 Oct 2, 2026 | $90.6M | 83 5-pillar Oct 4, 2026 | |
| $9.75 Oct 2, 2026 | $88.2M | 79 5-pillar Oct 4, 2026 | |
| $9.75 Oct 2, 2026 | $690M | 77 5-pillar Oct 4, 2026 | |
| $4.49 Oct 2, 2026 | $184M | 76 5-pillar Oct 4, 2026 | |
| $22.02 Oct 2, 2026 | $714M | 71 5-pillar Oct 4, 2026 | |
| $2.79 Oct 2, 2026 | $222M | 69 5-pillar Oct 4, 2026 | |
| $10.94 Oct 2, 2026 | $626M | 68 5-pillar Oct 4, 2026 | |
| $5.71 Oct 2, 2026 | $206M | 67 5-pillar Oct 4, 2026 | |
| Ensysce Biosciences (ENSC) — this page | $0.395 | $6.07M | 19 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Available records within the last 180 days, newest dated Aug 7, 2026 (coverage not recorded)
- Transactions
- 3
- Identified insiders
- 1
- Purchases
- 2
- Sales
- 0
- Other transactions
- 1
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Ensysce Biosciences (ENSC)?
- Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
- Ensysce Biosciences Completes Enrollment In Final Stage Of PF614-MPAR-102 Clinical Study
- Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
- Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
Ensysce Biosciences Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ENSC research dossier (written Jun 1, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ENSC?
ENSC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel pain relief and overdose protection technologies.
Is ENSC a good stock to buy?
Stock Expert AI does not rate ENSC buy, sell or hold. Ensysce Biosciences, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ENSC stock price today?
The last price recorded on this page for Ensysce Biosciences, Inc. (ENSC) is $0.395, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ENSC?
The main risks for Ensysce Biosciences, Inc. include the inherent risks associated with clinical-stage pharmaceutical companies, such as the possibility of unsuccessful clinical trial outcomes and failure to obtain regulatory approval from the FDA. The company's high cash burn rate and dependence on securing additional funding also pose financial risks.
What are the key factors to evaluate for ENSC?
Ensysce Biosciences, Inc. (ENSC) holds a MoonshotScore in the low range. Ensysce Biosciences is a clinical-stage pharmaceutical company focused on developing abuse-resistant and overdose-resistant opioid prodrugs. Not financial advice.
How frequently does ENSC data refresh on this page?
ENSC's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ENSC's recent stock price performance?
Ensysce Biosciences, Inc. (ENSC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative TAAP and MPAR technology platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ENSC overvalued or undervalued right now?
Ensysce Biosciences, Inc. (ENSC) is loss-making, so its trailing P/E is negative (-0.22x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ENSC before investing?
Before investing in Ensysce Biosciences, Inc. (ENSC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (18 figures)
The 18 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 10 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.395 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T00:54:35.889Z. | |
px.change | Change on the day | -1.20% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $6.07M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-05T00:54:34.724Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.0048 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $1M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -0.22 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 174.0K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$3M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 3 transactions · 2 purchases, 0 sales, 1 other transactions · 1 identified insiders · available records within the last 180 days, newest dated Aug 7, 2026 (coverage not recorded) | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-08 · Expired observation | |
px.range52 | 52-week range | $0.23 – $2.75 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.employees | Employees | 9 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.ceo | Chief executive | D. Lynn Kirkpatrick | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
fin.scores | Distress and quality screens | Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | current ratio 0.70 | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 19 of 100 · Weak · pillars 21 / 15 / 2 / 11 / 37 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 19 (stored snapshot Oct 3, 2026) → 19 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.